Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection

Clinical Neurology

Volumn 51, Issue 5, 2011, Pages 305-315

  Kamiya, Tatsushi ^a   Abe, Koji ^b  

^a Kamiya Iin ^*  (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Acute ischemic stroke; Ischemic cell death; Neuroprotection; Therapeutic time window; Thrombolysis

Indexed keywords

ALTEPLASE; ANTIFIBRINOLYTIC AGENT; EDAVARONE; SCAVENGER; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; JAPAN; NEUROPROTECTION; REVIEW; STROKE; TREATMENT FAILURE;

AMINES; ANIMALS; ANTIPYRINE; CEREBRAL INFARCTION; CYCLOHEXANECARBOXYLIC ACIDS; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; GAMMA-AMINOBUTYRIC ACID; HUMANS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79959458284     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: 10.5692/clinicalneurol.51.305     Document Type: Review

References (48)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger. Edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-229.
3. Pulsinelli WA. Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-536.
4. Pulsinelli WA, Jacewicz M, Levy DE, et al. Ischemic brain injury and the therapeutic window. Ann NY Acad Sci 1997;835:187-193. (Pubitemid 28046106)
5. Kamiya T, Jacewicz M, Nowak TS Jr, et al. Cerebral blood flow thresholds for mRNA synthesis after focal ischemia and the effect of MK-801. Stroke 2005;36:2463-2467.
6. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354. (Pubitemid 30078164)
7. Gelmers HJ, Hennerici M. Effects of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke 1990;21 (Suppl):IV81-84.
8. Horn J, Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 2001;32:570-576. (Pubitemid 32155253)
9. Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke treatment A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-2551.
10. Lyden P, Shuaib A, Ng K, et al. Clomethiazole acute stroke study in ischemic stroke (CLASS-I): final results. Stroke 2002;33:122-128. (Pubitemid 34052197)
11. Clark WM, Raps EC, Tong DC, et al. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000;31:1234-1239. (Pubitemid 30351239)
12. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988;19:211-216. (Pubitemid 18084395)
13. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-2597.
14. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988;19:480-485.
15. Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council. Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the Early Management of Adults With Ischemic Stroke. Stroke 2007;38:1655-1711.
16. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 2010;11:1-11.
17. Nito C, Kamiya T, Ueda M. et al. Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in rats. Brain Res 2004;1008:179-185. (Pubitemid 38624047)
18. Tateishi N, Mori T, kagamiishi Y, et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: Suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic asid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002;22:723-734. (Pubitemid 34596465)
19. Moskowitz MA. The Adventures of a Translational Researcher in Stroke and Migraine. Stroke 2007;38:1645-1651.
20. Toshima Y, Satoh S, Ikegaki I, et al. A New Model of Cerebral Microthrombosis in rats and neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000;31:2245-2250.
21. Lees KR, Zivin JA, Aswood T, et al. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:2644-2647.
22. Shuaib A, Lees KR, Lydan P, et al. Stroke-Acute Ischemic NXY Treatment (SAINT II) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med 2007;357:562-571.
23. Zhang WR, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004;26:342-348. (Pubitemid 38620058)
24. Okubo S, Igarashi H, Kanamatsu T, et al. FK506 extended the therapeutic time window for thrombolysis without inceasing the risk of hemorrhagic transformation in an embolic rat stroke model. Brain Res 2007;1143:221-227. (Pubitemid 46440820)
25. Hacke W, Kaste M, Bluhmki E, et al. for the European Co-operative Acute Stroke Study (ECASS) Investigators. Alteplase compared with placebo within 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
26. Lees KR, Bluhmki E, Von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
27. Wahlgren N, Ahmed N, Dávalos A, et al. for the SITS Investigators. Thrombolysis with alteplase 3-4.5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-1309.
28. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke MOnitoring STudy (SITSMOST). Lancet 2007;369:275-282. (Pubitemid 46138121)
29. Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable Analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials. Safe Implementation of Thrombolysis in Stroke MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316-3322.
30. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of on-set. Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-1815. (Pubitemid 44297734)
31. Nakagawara J, Miriematsu K, Okada Y, et al. Thrombolysis with 0.6mg/kg intravenous Alteplase for acute ischemic stroke in routine clinical practice: The Japan post-Marking Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-1989.
32. Mori E, Minematsu K. Nakagawara J, et al. Effects of 0.6 mg/kg intravenous Alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010;41:461465.
33. del Zoppo GJ. Stroke and neurovascular protection. N Engl J Med 2006;354:553-555.
34. McColl BW, Rose N, Robson FH, et al. Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab 2010;30:267-272.
35. Tsuji K, Aoki T, Tejima E, et al. t-PA promotes MMP-9 upregulation after transient focal cerebral ischemia Stroke 2005;36:1954-1959.
36. Yagi K. Kitazato KT, Uno M, et al. Edaravone. a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;410:626-631.
37. Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009;29:715-725.
38. Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients. General Outcomes and prognostic factors from the SAMURAI register. Stroke 2009;40:3591-3595.
39. Nezu T, Koga K, Kimura Y, et al. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA registry. Neurology 2010;75:555-561.
40. Lin N, Deguchi K, Shang J, et al. In vivo optical imaging of early-stage apoptosis in mouse brain after transient cerebral ischemia. J Neurosci Res 2010;88:3488-3497.
41. Fagan SC, Wailer JL, Nichois FT, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 2010;41:2283-2287.
42. Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602.
43. Palesch YY, Hill MD, Ryckborst KJ, et al. The ALLIAS Pilot Trial: a dose-escalation and safety of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 2006;375107-2114.
44. Chan PH. Future targets and cascades for neuroprotective strategies. Stroke 2004;35 [suppl I]:2748-2750. (Pubitemid 39458385)